21 U.S. Code § 356g - Standards for regenerative medicine and regenerative advanced therapies
Not later than 2 years after December 13, 2016, the Secretary, in consultation with the National Institute of Standards and Technology and stakeholders (including regenerative medicine and advanced therapies manufacturers and clinical trial sponsors, contract manufacturers, academic institutions, practicing clinicians, regenerative medicine and advanced therapies industry organizations, and standard setting organizations), shall facilitate an effort to coordinate and prioritize the development of standards and consensus definition of terms, through a public process, to support, through regulatory predictability, the development, evaluation, and review of regenerative medicine therapies and regenerative advanced therapies, including with respect to the manufacturing processes and controls of such products.
2017—Subsec. (b)(1)(A). Pub. L. 115–52 substituted “identify” for “identity”.
LII has no control over and does not endorse any external Internet site that contains links to or references LII.